Unmet needs in patients with acute myeloid leukemia ineligible for intensive approaches: perspectives from a European expert panel

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Ferrara F.
  • Geissler K.
  • Mehta P.
  • Venditti A.

Grupos

Abstract

Abstract no disponible

Datos de la publicación

ISSN/ISSNe:
2234-943X, 2234-943X

Frontiers in Oncology  FRONTIERS MEDIA SA

Tipo:
Article
Páginas:
-
Enlace a otro recurso:
www.scopus.com
Factor de Impacto:
1,291 SCImago ℠
Cuartil:
Q1 SCImago ℠

Documentos

  • No hay documentos

Métricas

Filiaciones

Filiaciones no disponibles

Keywords

  • antineoplastic agent; apvo436; azacitidine; azd5991; bleximenib; CD135 antigen; crelosidenib; crenolanib; cusatuzumab; decitabine; emavusertib; emirodatamab; enasidenib; entinostat; entospletinib; eprenetapopt; evorpacept; ff 10101; flotetuzumab; gilteritinib; h3b 8800; hypomethylating agent; iadademstat; ipilimumab; isocitrate dehydrogenase 1; isocitrate dehydrogenase 2; ivosidenib; jnj 74856665; lemzoparlimab; luxeptinib; milademetan; nivolumab; olaparib; pembrolizumab; pevonedistat; pinometostat; pivekimab sunirine; ponatinib; protein p53; prt543; relatlimab; revumenib; s55746; s64315; s65487; sabatolimab; siremadlin; spartalizumab; tamibarotene; tapotoclax; tuspetinib; unclassified drug; uproleselan; vadastuximab; venetoclax; vibecotamab; vixtimotamab; ziftomenib; acute myeloid leukemia; allogeneic hematopoietic stem cell transplantation; Article; cancer chemotherapy; cancer incidence; cancer prognosis; Charlson Comorbidity Index; clinical assessment; cognition; cognitive defect; c

Cita

Compartir